-

$undefined

N/A

(N/A)

Relay Therapeutics NASDAQ:RLAY Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Location: 399 Binney Street, 2nd Floor, MA, 02139, US | Website: relaytx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-276.8M

Cash

781.3M

Avg Qtr Burn

-62.28M

Short % of Float

15.09%

Insider Ownership

1.80%

Institutional Own.

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RLY-2608 + fulvestrant Details Cancer, PI3Kα-mutated, HR+/HER2- advanced breast cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-2608 Details Vascular Malformations	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-4008 (Lirafugratinib) Details Solid tumor/s, Intrahepatic cholangiocarcinoma , Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-2608 + fulvestrant (doublet) Details Cancer, 2L PI3Kα-mutated, HR+/HER2- locally advanced or metastatic breast cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-2608 + fulvestrant + ribociclib (triplet) Details Cancer, 1L PI3Kα- mutated, HR+, HER2- metastatic breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RLY-1971 (GDC-1971) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.